Deadline on June 25th coming up in Lawsuit for Investors who lost money with shares of Akero Therapeutics, Inc. (NASDAQ: AKRO)

A deadline is coming up on June 25, 2024 in the lawsuit filed for certain investors of Akero Therapeutics, Inc. (NASDAQ: AKRO) over alleged securities laws violations by Akero Therapeutics, Inc. (NASDAQ: AKRO).

Investors who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) have certain options and there are strict and short deadlines running. Deadline: June 25, 2024. NASDAQ: AKRO stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of Akero Therapeutics, Inc. (NASDAQ: AKRO) common shares between September 13, 2022 and October 9, 2023, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between September 13, 2022 and October 9, 2023, the defendants made false and/or misleading statements and/or failed to disclose that approximately 20% of the patients enrolled in the SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline, that the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH, that the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints, that Akero had introduced a confounding factor into the SYMMETRY study's design, materially influencing the study's potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not ruled out potential causes of each patient's cirrhosis other than NASH, and that consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.

Those who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.